Prostate-specific membrane antigen (PSMA)-targeted AuNPs improve therapeutic specificity and efficacy by precisely delivering AuNPs to prostate cancer cells while minimizing off-target effects [368]. The gene discussed is FOLH1; the disease is prostate cancer.